The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its Na v 1.8 inhibitors, which are being developed as non-opioid treatments for ...

If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.

The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.

Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...

“Oil field-wise we should be okay, to start out with but there could be massive shortages ahead and we can’t handle that,” explained Kirk Edwards, President of Latigo Petroleum. From the ...

THOUSAND OAKS, Calif., March 17, 2025 /PRNewswire/ -- Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain at ...